XENON PHARMACEUTICALS INC (XENE)
Health Care · Biotechnology · NASDAQ
A clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapies for the treatment of neurological disorders.
What XENON PHARMACEUTICALS INC does
Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders. The company's primary research and development efforts are dedicated to advancing its pipeline of product candidates, with a lead focus on azetukalner for various indications.
Themes: neurological disorders, small-molecule drugs
Fundamentals
- Price$36.16 as of 2026-10-08 close
- Market cap$3.5B as of 2026-08-03 (share count; price 2026-10-08)
- 1-year return-7.9% 2025-10-08 close $39.25 → 2026-10-08 close $36.16
- P/En/a negative earnings
- ROE-59.5% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Revenue growth (YoY)-7.3% as of 2026-09-02
- Revenue CAGR (3y)-77.8% SEC XBRL
- Beta0.94 as of 2026-09-02
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How XENE compares in its sector
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
XENE is not currently in any published Top 10 list. Its scores are below.
Top 10 score
30.8 #1344 of 1,379 scored · #146 of 151 in Health Care
Financial health 94th (debt to equity 0) and valuation 56th (price to book 2.8); weakest is profitability (2nd, return on equity -59.5%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How XENON PHARMACEUTICALS INC looks technically
XENON PHARMACEUTICALS INC (XENE) is trading 31.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 259 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 47, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 22, in oversold territory (below 30). MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive). It just made a new 20-day low, breaking below its recent trading range. It is 3.1% above its 52-week low (its lowest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 31.6% below its 200-day average, the long-term trend line — a long-term downtrend | -31.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $54.18 | $54.18 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $52.88 | $52.88 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 64 calendar days ago — the swings before that are what the structure reading is measured on | 64 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 66.225. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 259 trading days ago — a "golden cross", a bullish long-term signal | 259 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 47, with sellers in control | 46.8 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 22, in oversold territory (below 30) | 21.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($35.06 to $40.26) — its "stochastic" reading is 21 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 21.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $72.66 | $72.66 |
|---|---|---|
| From the 52-week high | it is 50.2% below its 52-week high (its highest price of the past year) | -50.2% |
| Above the 52-week low | it is 3.1% above its 52-week low (its lowest price of the past year) | +3.1% |
| Below the 52-week high | it is 50.2% below its highest point of the past year | 50.2% |
| Since a 20-day breakout | it just made a new 20-day low, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $72.66 (set on 2026-07-09) | $72.66 |
| Given back of the 52-week move | over the past year its closes ranged ($36.16 to $70.96), and it has recovered essentially none of its fall from last year’s high — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $57.67 to $58.78. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 50.2% below its all-time high | -50.2% |
| Nearest price level | it is trading 1.0% above a support level at $35.78 — a price it turned at twice since 2025-09-15, most recently on 2025-09-25. Since 2024-10-08 it has 3 such levels below the current price and 12 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.0% |
| All-time low | its lowest closing price on record is $2.10 (set on 2017-11-16) | $2.10 |
| Above the all-time low | it is 1621.9% above its all-time low | +1,622% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 94% of the past ~6 months) | 94th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.12 between its high and its low — about 5.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.12 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $25.27 and $59.87 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $25.27 – $42.57 – $59.87 |
| Typical daily range (% of price) | its price moves about 5.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.8% |
| Stretch from the 200-day average | it is trading 7.9 daily ranges below its 200-day average price (31.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.9 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.98× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 1.3% since the prior reading | -1.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
4
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a hammer | 8 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 8 sessions ago |
| Since a bullish engulfing | 7 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 7 sessions ago |
| Since a bearish engulfing | 4 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 4 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.6% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.6% |
|---|---|---|
| Open gap | it gapped 23.2% below the previous close 14 sessions ago and has not traded back through the level it left behind at 57.35 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -23.2% |
| Gap filled | a 3.0% gap up opened on 2026-10-01 has been "filled" 3 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 3 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 5 sessions in a row, a -7.12% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 5 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 40.3 percentage points (the stock lost 39.3% while the market gained 1.0%) | -40.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 52.1 percentage points (the stock lost 48.3% while the market gained 3.8%) | -52.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 53.8 percentage points (the stock lost 36.4% while the market gained 17.5%) | -53.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 22.9 percentage points (the stock lost 7.9% while the market gained 15.0%) | -22.9% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, its RSI momentum gauge is oversold (a beaten-down reading), MACD momentum is positive — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 42% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.3% of the share price, which is taken to mean a barrier that gives way easily. | -42.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 30% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $51.93 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | -30.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 19% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $44.37 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -18.5% |
Price levels it has turned at before
XENE last closed at $36.16 on 2026-10-08. Since 2024-10-08 it has turned at 3 prices below its last close and 12 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $35.78 | Support | 1.0% below the last close | turned there twice · 2025-09-15 to 2025-09-25 |
| $37.33 | Resistance | 3.2% above the last close | turned there five times · 2024-11-18 to 2025-11-07 |
| $38.06 | Resistance | 5.3% above the last close | turned there three times · 2025-01-23 to 2025-09-17 |
| $33.59 | Support | 7.1% below the last close | turned there four times · 2025-02-28 to 2025-07-03 |
| $39.24 | Resistance | 8.5% above the last close | turned there four times · 2025-05-01 to 2026-01-20 |
| $28.34 | Support | 21.6% below the last close | turned there twice · 2025-05-13 to 2025-05-30 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $66.22.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Broke down to a new 20-day low · MACD just crossed bullish (12/26/9) · Analyst price target recently CUT | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.26 mean, 1=Strong Buy…5=Strong Sell) — 18 analysts
- Mean price target$73.37 range $46.00 – $97.00; median $73.50
Analyst estimates, as of 2026-10-07. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for XENE
- Consensus EPS estimate-$1.15 next reporting period, as of 2026-10-07
- Estimate change, 30 days+$0.00856 from -$1.16, on 2026-09-02, 35-day window
- Readings revised upward38% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of significant operating losses and no commercial revenue to date.","High risk of clinical trial failure and inability to obtain regulatory approval for product candidates.","Need for substantial additional capital and potential dilution of shareholders to fund ongoing R&D and commercialization efforts."]
What changed in the latest 10-Q
AI-assisted comparison of XENE's 10-Q filed 2026-05-07 against the prior one filed 2025-11-03.
Risk Factors
- Reworded:
- Net loss figures updated from '$240.6 million and $168.6 million for the nine months ended September 30, 2025 and 2024' (filed 2025-11-03) to '$102.3 million and $65.0 million for the three months ended March 31, 2026 and 2025' (filed 2026-05-07)
- Accumulated deficit updated from '$1,140.1 million as of September 30, 2025' (filed 2025-11-03) to '$1,347.7 million as of March 31, 2026' (filed 2026-05-07)
- Page number changed from '- 24 -' (filed 2025-11-03) to '- 25 -' (filed 2026-05-07)
- Notes:
- Both filings appear truncated at the end of the final paragraph; comparison limited to complete text available
- Financial figures reflect different reporting periods (nine months vs. three months) so are not directly comparable on a per-period basis
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
2 open-market purchases and 3 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-042 buys ($2M) · 0 sells — 2 buying insiders
- Last 90 days · read to 2026-10-042 buys ($2M) · 3 sells ($1M) — 2 buying, 2 selling insiders
- Last 180 days · read to 2026-10-042 buys ($2M) · 5 sells ($1M) — 2 buying, 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-30. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about XENE's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding XENE as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 22,223,503
- Reported value $1,341,409,079
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about XENE's institutional holders → See what each manager we track holds →
Short interest (FINRA)
XENE had 6,444,815 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
XENE had 6.66% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.22 days to cover at the same settlement.
- Reported short interest (shares) 6,444,815
- Short interest (% of shares outstanding) 6.66%
- Prior settlement (shares) 6,344,135
- Reported change 1.59%
- Days to cover (reported) 12.22
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Frequently asked questions
What does XENON PHARMACEUTICALS INC (XENE) do?
Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders. The company's primary research and development efforts are dedicated to advancing its pipeline of product candidates, with a lead focus on azetukalner for various indications.
What sector is XENON PHARMACEUTICALS INC (XENE) in?
XENON PHARMACEUTICALS INC (XENE) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Is XENON PHARMACEUTICALS INC (XENE) overbought or oversold right now?
XENON PHARMACEUTICALS INC (XENE) is currently in oversold territory (its 14-day RSI is 22, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on XENE come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.